50 mg of KX2-391 Ointment 1% + 50 mg of KX2-391 Ointment 1%

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Actinic Keratosis

Conditions

Actinic Keratosis

Trial Timeline

Apr 11, 2016 → Dec 22, 2017

NCT ID

NCT02838628

About 50 mg of KX2-391 Ointment 1% + 50 mg of KX2-391 Ointment 1%

50 mg of KX2-391 Ointment 1% + 50 mg of KX2-391 Ointment 1% is a phase 2 stage product being developed by Almirall for Actinic Keratosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02838628. Target conditions include Actinic Keratosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02838628	Phase 2	Completed	Apr 11, 2016	Dec 22, 2017	Actinic Keratosis

Competing Products

20 competing products in Actinic Keratosis

See all competitors

Product	Company	Stage	Hype Score
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%	Sun Pharmaceutical	Phase 3	77
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%	Sun Pharmaceutical	Phase 3	77
Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical Gel	Sun Pharmaceutical	Phase 1	33
Imiquimod Topical Cream 3.75% + Zyclara® (imiquimod) Topical Cream 3.75% + Vehicle Topical Cream	Sun Pharmaceutical	Phase 1	33
Imiquimod 5% manufactured by Taro + Aldara - Imiquimod 5% + Imiquimod Vehicle manufactured by Taro	Sun Pharmaceutical	Phase 1	33
Investigational Treatment + Active comparator	Novartis	Phase 2	52
KX01 ointment 1% + Placebo	PharmaEssentia	Phase 3	76
Fluorouracil	Sanofi	Phase 1/2	40
fluorouracil cream 0.5%	Sanofi	Approved	84
Imiquimod + Diclofenac	Viatris	Approved	82
Imiquimod 5 % Cream	Viatris	Phase 2	49
Imiquimod	Viatris	Pre-clinical	20
Aldara (Imiquimod)	Viatris	Phase 3	74
Imiquimod + Diclofenac	Viatris	Approved	82
Low dose DFD07 once daily + High dose DFD07 once daily + High dose DFD07 twice daily + Placebo twice daily	Dr. Reddy's Laboratories	Phase 2/3	62
Placebo Gel + LAS41005 + LAS106521	Almirall	Phase 3	72
5-fluorouracil/salicylic acid + Vehicle	Almirall	Phase 3	72
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% Gel	Almirall	Approved	80
KX2-391 Ointment 1% + Placebo	Almirall	Phase 3	72
Tirbanibulin 2.5 mg ointment	Almirall	Approved	80

Other Products from Almirall

TildrakizumabApproved

Tiotropium + AclidiniumApproved

Dimethyl fumarate (DMF) standard scheme + Dimethyl fumarate (DMF) simplified scheme + TildrakizumabApproved

Pidotimod + PlaceboApproved

Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelApproved